| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/096120301678416033 |
| P698 | PubMed publication ID | 11480845 |
| P2093 | author name string | D J Wallace | |
| M H Weisman | |||
| C F Remer | |||
| P2860 | cites work | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans | Q47682285 | ||
| Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. | Q52225534 | ||
| Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. | Q52916966 | ||
| P433 | issue | 7 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| P304 | page(s) | 480-483 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | |
| P478 | volume | 10 |
| Q58747430 | A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study |
| Q33757883 | Advances in drug therapy for systemic lupus erythematosus |
| Q40476936 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. |
| Q35968394 | Challenges in bringing the bench to bedside in drug development for SLE. |
| Q35091815 | Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis. |
| Q36443689 | Contemporary treatment of systemic lupus erythematosus: an update for clinicians. |
| Q26741266 | Current and emerging treatment options in the management of lupus |
| Q36171764 | Disease activity assessment in SLE: do we have the right instruments? |
| Q45088819 | Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q41781500 | Effect of leflunomide on immunological liver injury in mice |
| Q38101015 | Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review |
| Q37185408 | Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial |
| Q36066014 | Emergence of targeted immune therapies for systemic lupus |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q50493859 | Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience. |
| Q46484874 | Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study |
| Q50788916 | Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. |
| Q37908152 | Leflunomide: dermatologic perspective |
| Q28274721 | Leflunomide: friend or foe for systemic lupus erythematosus? |
| Q37754815 | Management of systemic lupus erythematosus in Chinese patients |
| Q35148630 | Novel Approaches to Therapy for SLE. |
| Q37754557 | Novel approaches to therapy for systemic lupus erythematosus: update 2005. |
| Q51608298 | Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy. |
| Q83275586 | Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy |
| Q37358239 | Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q35953478 | Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. |
| Q90260400 | Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects |
| Q44871900 | Subacute cutaneous lupus erythematosus associated with leflunomide |
| Q46729928 | Subacute cutaneous lupus erythematosus precipitated by leflunomide |
| Q37807147 | Systemic Lupus Erythematosus: Safe and Effective Management in Primary Care |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q26775707 | The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis |
| Q46146983 | The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy |
| Q38540167 | The evolution of drug discovery in systemic lupus erythematosus |
| Q36577380 | The management of pediatric systemic lupus erythematosus |
| Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
| Q42728756 | Treatment of lupus nephritis |
| Q38973692 | Trigger factors of cutaneous lupus erythematosus: a review of current literature. |
| Q37690745 | Update on emerging drug therapies for systemic lupus erythematosus |
| Q35823414 | Update on the immunology, diagnosis and management of systemic lupus erythematosus |
| Q80984232 | [Therapeutical perspectives in systemic lupus erythematosus] |
Search more.